Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions

Biosimilar Primer:
US Physicians’
Attitudes, Beliefs, and
Intentions
Info@ISRreports.com

©2014 Industry Standard Research www.ISRreports.com
PREVIEW

www.ISRreports.com ©2014 | Preview of: Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 2
act with confidence
Report Overview
This report features survey data portraying the perspectives of US physicians (cardiologists, CNS/
neurologists, oncologists, PCP, and respiratory/ pulmonologists) regarding their familiarity and prescription
propensity for biosimilar products. This is not ISR’s first report on the views that US physicians hold
regarding biosimilars. In comparison to our 2013 Biosimilar Primer report, physician familiarity with
biosimilars has increased. With this data, biopharmaceutical companies, payers, and service providers can
make more informed decisions regarding product marketing, delivery, and manufacturing.
28Charts and Graphs
173Respondents
31Pages
Executive summary
Familiarity with biosimilars
Prescribing and pricing
• Medicine identification
• Likelihood of prescribing a recently approved biosimilar
• Discount required for physician recommendation
Switching and DAW preference
• Importance of being notified of pharmacy-level substitution
• Opinion on EU ban on pharmacy-level substitution
• Expected biologic prescriptions to be written with a DAW clause
• Likelihood to use DAW clause
• Preferred clinical testing for biosimilars
Demographics
Report Structure:
Respondent Demographics:
What you will learn in this report:
ISR’s report surveyed board certified cardiologists, CNS/ neurologists, oncologists, PCP, and
respiratory/ pulmonologists in the U.S. to gain insight into:
• The level of familiarity physicians have with biosimilars
• Intentions for prescribing based on biosimilar pricing
• Opinions of pharmacy switching
• Beliefs on the required clinical development process for biosimilar approval
173
Number of Participants Area of Board Certiﬁcation Practice Type
Physician-owned
private practice: 58%
Large physician-owned
group practice: 23%
Integrated patient/hos-
pital network: 19%
Cardiology (N=30)
Neurology (N=32)
Oncology (N=32)
Primary Care (N=48)
Pulmonology (N=31)

act with confidence
Familiarity with Biosimilars
Prescribing and Pricing
Medicine Identification - Understand how physicians identify medicines when writing a
prescription (i.e. by brand name, generic name, or NDC number)
Biosimilar vs. The Original Compound - Prescribing Likelihood – If a payer recommends a
biosimilar (via reimbursement levels), how likely would a physician be to prescribe the biosimilar
vs. the original compound?
Pricing of Biosimilar Products – What pricing expectations do physicians have for biosimilars? At
what price would a physician recommend a biosimilar product over the original compound?
Switching and DAW Preferences
Importance of Pharmacy Notification if Different Drug Dispensed – How important is it that
physicians are notified by the pharmacist when a patient receives a biologic medicine other than
the one prescribed?
Opinion on EU ban on Pharmacy-level Substitution — Many EU countries have mandated that
there can be no pharmacy-level substitution for biosimilar products. What do physicians think of
this ban?
Pharmacy Level Substitutions – Understand physicians’ thoughts on pharmacy-level substitutions
for biosimilar products.
When to Use DAW Clause – How do physicians use the DAW clause differently when prescribing
chemical and biological products?
Frequency of DAW Prescriptions Written for Biosimilars – How often will physicians write the
“DAW” clause for biologics with a biosimilar option?
Preferred Clinical Testing for Biosimilars — Do physicians think biosimilars should have
full-fledged clinical trials or follow chemical generics and just require pharmacodynamics,
pharmacokinetic, and bioequivalence testing?
More Concerned about Safety or Efficacy — Are physicians most concerned with a new biosimilar
product’s safety, efficacy, or neither?
Report Contents

act with confidence
Table of Contents
For full table of contents and additional sample pages, please download the
full preview from ISR’s website:
http://www.isrreports.com/product/biosimilar-primer-us-physicians-atti-
tudes-beliefs-and-intentions/

act with confidence
act with confidence
Introduction
www.ISRreports.com ©2014 | Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions 4
Introduction
As the old adage goes, the only certainties in life are: death, taxes, and increased
biosimilar commercialization. The following are examples of biosimilar activity taken
from pharmaceutical industry publications during a two week period in April, 2014.
• Boehringer Ingelheim’s chairman stated, “We see biosimilars as a future growth
field.” BI’s most advanced biosimilar is a version of Sanofi’s insulin Lantus,
which is being developed in partnership with Lilly and is currently undergoing
regulatory review in Europe with a view to launch some point this year in the
region. A US launch is planned for 2015.
• Epirus Pharmaceuticals raised $36M to fund its biosimilar work, with a lead
Phase III program for a Remicade knockoff along with follow-up programs for
Humira and Avastin. Epirus’ strategy is to launch biosimilars outside of the US and
Europe in hopes of improving their changes with local regulators while gaining
government support to build facilities and win government contracts for lower-
priced therapies.
• Baxter is teaming up with Coherus BioSciences to develop a copy of Amgen and
Pfizer’s Enbrel with plans to file for FDA approval in 2016.
• Hospira persuaded a U.K. court to overturn two Herceptin patents, which means
biosimilar competition could arise there at any time.
• Catalent signed a deal to lend its biologics development technology to China’s
Zhejang Hisun Pharmaceuticals. Under the agreement Catalent will supply the
technology to develop biosimilars of Remicade, Humira, and Lemtrada. Catalent
says its system can get biologics projects into the clinic three times faster than
other approaches.
• France passed a law that gives pharmacists the ability to substitute biosimilar
drugs for the original. It only applies to patients who are starting a new course of
treatment and who are getting products from retail pharmacies (not hospitals)
and still allows the physicians to demand the original biologic product.
• Japanese drugmaker Kyowa Hakko Kirin, who is partnering with Fuji to develop
biosimilars, just finished construction on a new biologics plant and should be
ready for operations in 1H2016.
This report features survey data concerning the perspectives of US physicians
(cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists)
regarding their familiarity and prescription propensity for biosimilar products. This
is not ISR’s first report on the views that US physicians hold regarding biosimilars.
In comparison to our 2013 Biosimilar Primer report, physician familiarity with
biosimilars has increased. While the two research endeavors don’t exactly match in
Sample Page

act with confidence
Sample Page
For full table of contents and additional sample pages, please download the
full preview from ISR’s website:

act with confidence
Ordering Information
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services
industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.

For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at
www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
About Industry Standard Research
Save on this,
or any ISR
report, by
registering a
free account
Register now
• Receive a $250 instant credit towards any ISR report
• Earn 10% credit towards all future purchases
• Receive advanced notifications on ISR’s latest reports and free resources
For pricing and ordering information, please visit:

act with confidence
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 8
act with confidence
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 10
act with confidence
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10
act with confidence
The ISR Difference
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
The Common
Syndicated Reportvs.
How confident are you?
vs.
DataCollection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
Struggle to recruit the right
targets and enough of them
vs.
SampleSizes
Robust sample sizes that
instill confidence
Often insufficient industry
representation that leaves you
defending results
vs.vs.
Research methods
Mostly primary
research;
always appropriate
for the topic
One size fits all;
usually publically
available data
vs.vs.
Respondents
Sophisticated screening
ensures genuine
decision-makers
Undisclosed
methodologies and
respondent demographics
vs.vs.
Analysts
Decades of experience
means more insights that are
immediately usable
Junior analysts capable of
reporting numbers

Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions

Recomendados

Recomendados

Más contenido relacionado

Más de Industry Standard Research

Más de Industry Standard Research (20)

Último

Último (20)

Biosimilar Primer: US Physicians’ Attitudes, Beliefs, and Intentions